"Argo" is the name of a ship in ancient Greek mythology, and the individuals aboard were known as Argonauts. These heroes successfully navigated through numerous challenges to obtain the Golden Fleece. The story of their heroic quests, bravery, and triumph serves as the inspiration behind "Argo Biopharma."
"Argo" is the name of a ship in ancient Greek mythology, and the individuals aboard were known as Argonauts. These heroes successfully navigated through numerous challenges to obtain the Golden Fleece. The story of their heroic quests, bravery, and triumph serves as the inspiration behind "Argo Biopharma."
Argo Biopharma is a clinical stage biotech company that committed to developing a new generation of siRNA drugs to provide better treatments for global patients.
In the past three years, Argo biopharma has built a rich and differentiated pipeline of siRNA drug candidates for a wide range of indications, utilizing its industry-leading siRNA platform technology known as RADS (RNA molecules with superior Activity, Durability, and Safety).
Led by an experienced and professional team, Argo Biopharma has demonstrated scientific excellence in siRNA drug discovery and strong execution in advancing potential therapeutic products from discovery to clinical stage.
Advance the field of RNA technology and create transformative medicines for chronic disease management
Become a leading RNA therapeutics explorer
Co-founder, CEO
Dr. Shu is a co-founder of Argo Biopharma. Before Argo, Dr. Shu served as a senior scientist at Arrowhead Pharmaceuticals, where he focused on developing extrahepatic delivery platforms, some of which are successfully applied in clinical studies. Prior to Arrowhead, Dr. Shu conducted his postdoctoral research at Northwestern University. Dr. Shu received his Ph.D. in chemistry from the University of Wisconsin-Madison, and his B.S. from Peking University.
Co-founder, CSO
Dr. Shao is a co-founder of Argo Biopharma with over two decades of experience in drug research and development. Prior to his role at Argo, he led research and development at Mitotherapeutix, a startup specializing in siRNA-based new drug discovery for treating NASH. Preceding this, he held the position of Director of Medicinal Chemistry at Arrowhead Pharmaceuticals, leading efforts in extrahepatic delivery platforms and programs. His journey in drug discovery began at Merck Research Labs, where he served as a principal scientist involved in various projects spanning cardiovascular health, diabetes, oncology, and CNS disorders. Dr. Shao earned his Ph.D. in chemistry from University of Victoria and conducted postdoctoral research in natural product synthesis at University of Rochester.
CMO
Dr. Jin received his M.D. and Ph.D. from Shanghai Medical College, Fudan University. With 18 years of experience in MNC, he has played a leading role in Clinical Development and Medical Affairs at Wyeth, BI, and Lilly China. He also served as the Head of Clinical Development at Novartis China, where he successfully led the team in conducting the Asia Phase 3 study of siRNA drug LEQVIO® (inclisiran). Dr. Jin has extensive knowledge in various therapeutic areas including immunology, CNS, cardiovascular/metabolism, kidney disease, bone, infection, respiratory, ophthalmology, hematology, and oncology. Prior to joining Argo, he held the position of CMO at a domestic siRNA biotech company and was an operating partner at a healthcare investment firm. During his time there, he successfully incubated and established a renal biotech in China.
为了更好的呈现效果，移动端请竖屏浏览
